The FDA has approved Gazyva® (obinutuzumab) for adults and children ages 2 and older with idiopathic nephrotic syndrome that began in childhood and is frequently relapsing (FRNS) or steroid-dependent (SDNS). More information coming soon. Please visit our Patient Navigation tool for support.
Learn more about NephCure by accessing our latest IRS Form 990 and audit or on Guidestar.
NephCure
c/o Gardner, Pierce and Associates, P.C. – Accounting Department 5 Center Avenue, Suite D
Collegeville, PA 19426
1299 N. 7th St #16556
Philadelphia, PA 19122
Phone: 1-866-NephCure (637-4287)
Email: info@nephcure.org
NephCure is a registered non-profit (501c3) tax-exempt charitable organization. EIN # 38-3569922.
© Copyright 2024 NephCure, Inc. All rights reserved worldwide. NephCure, and the logo, are federally registered trademarks of NephCure, Inc.
EN 
ES 